Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 7/20 | 0.63 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.63 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.57 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | GFER | P55789 | 1/20 | 0.48 |
| ▸ | AR | P10275 | 1/20 | 0.48 |
| ▸ | CYP1A1 | P04798 | 2/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.48 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2112646 | 1.00 | NFE2L2 (0.63) | NFE2L2TRPA1CYP19A1PRMT1GAA | |
| SCHEMBL9840898 | 0.84 | CYP19A1 (0.53) | NFE2L2TRPA1CYP19A1GAACYP1A1 | |
| SCHEMBL9840908 | 0.84 | CYP19A1 (0.53) | NFE2L2TRPA1CYP19A1GAACYP1A1 | |
| SCHEMBL27841658 | 0.84 | NFE2L2 (0.56) | NFE2L2TRPA1CYP19A1PRMT1GAA | |
| SCHEMBL27841655 | 0.83 | CYP19A1 (0.58) | NFE2L2TRPA1CYP19A1CYP1A1CYP1A2 | |
| SCHEMBL10466720 | 0.81 | PRMT1 (0.72) | CYP19A1PRMT1GAAGFERAR | |
| SCHEMBL10466719 | 0.81 | PRMT1 (0.72) | CYP19A1PRMT1GAAGFERAR | |
| SCHEMBL5385330 | 0.81 | KDM4E (0.59) | NFE2L2PRMT1GAAGFERAR | |
| SCHEMBL5385338 | 0.81 | KDM4E (0.59) | NFE2L2PRMT1GAAGFERAR | |
| SCHEMBL3792954 | 0.80 | RAB9A (0.42) | NFE2L2TRPA1CYP19A1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1776347-B1 | SULPHONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | SANOFI AVENTIS (FR) | 2010-05-26 | — | — | EP | disclosed |
| US-7396958-B2 | Sulphonamide derivatives, their preparation and their therapeutic application | SANOFI AVENTIS (FR) | 2008-07-08 | — | — | US | disclosed |
| US-20070185136-A1 | SULPHONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | SANOFI-AVENTIS (FR) | 2007-08-09 | — | — | US | disclosed |
| EP-1776347-A1 | SULPHONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | Sanofi-Aventis (FR) | 2007-04-25 | — | — | EP | disclosed |
| WO-2006024779-A1 | SULPHONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | SANOFI-AVENTIS (FR) | 2006-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185136-A1 | SULPHONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | HCRTR2, GIPR, SSTR2 | NFE2L2 2700/4885TRPA1 695/4885CYP19A1 3475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.